Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended

2023-506587-13-00 Multiple Myeloma 4 2020-01-30
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study) Ended

2023-509461-20-00 pT3-4 cN0M0 Melanoma 4 2020-01-22
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended

2023-509550-55-00 Multiple Myeloma 7 2020-01-21
Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended

2023-509908-15-00 Mantle Cell Lymphoma 10 2020-01-20
A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia Ended

2024-514197-50-00 CD123 positive Acute Myeloid Leukemia 9 2020-01-17
NaDeJ (National Deescalation Study One) Ended

2024-517832-23-00 Human Papillomavirus oropharyngeal squamous cell carcin 4 2020-01-09
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou… Ended

2023-509049-11-00 FIGO stage III ovarian cancer who are eligible for prim 5 2020-01-01
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended

2023-503831-17-00 The treatment of participants with HRRm and/or HRD-posi 4 2019-12-23
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Malignant pleural mesothelioma (MPM) 10 2019-12-20
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal C… Ended

2024-513914-36-00 locally-advanced Anal Carcinoma, Anal cancer stage II a 4 2019-12-17
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cance… Ended

2024-517705-93-00 Histologically or cytologically confirmed diagnosis of 9 2019-12-13
Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended

2023-508830-33-00 Patients diagnosed with advanced or metastatic cancer t 4 2019-12-13
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have … Ended

2023-505088-35-00 Pediatric Solid tumors and primary central nervous syst 9 2019-12-12
ADP-A2M4 in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Ended

2024-512847-21-00 Advanced Synovial Sarcoma 4 2019-12-11
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy … Ended

2023-506258-19-00 oropharyngal cancer 5 2019-12-11
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit… Ended

2023-503829-18-00 Acute myeloid leukemia 4 2019-12-05
Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC… Ended

2023-508635-31-00 Hepatocellular Carcinoma 5 2019-12-03
A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early… Ended

2022-501102-35-00 Early triple negative breast cancer 5 2019-12-02
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administr… Ended

2023-507732-20-00 Advanced epithelial ovarian cancer stage III-IV 5 2019-11-29
Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d… Ended

2024-513039-26-00 non-small cell lung cancer stages IIIA (N2) and selecte 4 2019-11-25
A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula… Ended

2023-504303-86-00 High-risk hepatocellular carcinoma (HCC) 5 2019-11-21
Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of dr… Ended

2024-518473-34-00 Multiple Myeloma 5 2019-11-20